Recent Review on Subclass B1 Metallo-β-lactamases Inhibitors: Sword for Antimicrobial Resistance

Area of Science:

• Microbiology and Infectious Diseases
• Drug Discovery and Development
• Biochemistry

Background:

• The rise of antibiotic resistance in microbial pathogens presents a significant global health threat.
• Metalloβ-lactamase (MBL) enzyme production is a primary mechanism bacteria use to resist antibiotics.
• Current therapeutic options against MBL-producing bacteria are limited, necessitating novel treatment strategies.

Purpose of the Study:

• To review and discuss clinically relevant molecules that inhibit metalloβ-lactamase enzymes.
• To highlight potential therapeutic agents against various B1 metalloβ-lactamase variants.
• To address the urgent need for effective inhibitors to combat multidrug-resistant infections.

Main Methods:

• Literature review of existing research on metalloβ-lactamase inhibitors.
• Analysis of studies focusing on the efficacy of different molecular compounds against MBLs.
• Evaluation of clinically potent molecules targeting B1 metalloβ-lactamase variants.

Main Results:

• Identification of several promising inhibitor molecules with potential clinical application.
• Discussion of the inhibitory mechanisms and spectrum of activity of reviewed compounds.
• Highlighting the lack of clinically approved drugs against metallo-β-lactamase to date.

Conclusions:

• Development of broad-spectrum metalloβ-lactamase inhibitors is crucial for combating antibiotic resistance.
• Further research is needed to identify and develop effective drugs against MBL-producing bacteria.
• Targeting B1 metalloβ-lactamase variants with potent inhibitors offers a viable strategy against multidrug resistance.